| Title |
CD40 immunotherapy for pancreatic cancer
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2013
|
| DOI | 10.1007/s00262-013-1427-5 |
| Pubmed ID | |
| Authors |
Robert H. Vonderheide, David L. Bajor, Rafael Winograd, Rebecca A. Evans, Lauren J. Bayne, Gregory L. Beatty |
| Abstract |
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and lethal cancer which is poorly responsive to standard therapies. Although the PDA tumor microenvironment is considered especially immunosuppressive, recent data mostly from genetically engineered and other mouse models of the disease suggest that novel immunotherapeutic approaches hold promise. Here, we describe both laboratory and clinical efforts to target the CD40 pathway for immunotherapy in PDA. Findings suggest that CD40 agonists can mediate both T-cell-dependent and T-cell-independent immune mechanisms of tumor regression in mice and patients. T-cell-independent mechanisms are associated with macrophage activation and the destruction of PDA tumor stroma, supporting the concept that immune modulation of the tumor microenvironment represents a useful approach in cancer immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | <1% |
| Unknown | 106 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 22% |
| Student > Ph. D. Student | 17 | 16% |
| Student > Bachelor | 13 | 12% |
| Student > Master | 10 | 9% |
| Other | 8 | 7% |
| Other | 22 | 21% |
| Unknown | 13 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 28% |
| Agricultural and Biological Sciences | 21 | 20% |
| Immunology and Microbiology | 18 | 17% |
| Biochemistry, Genetics and Molecular Biology | 13 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 6 | 6% |
| Unknown | 16 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2021.
All research outputs
#3,445,711
of 25,002,811 outputs
Outputs from Cancer Immunology, Immunotherapy
#225
of 2,953 outputs
Outputs of similar age
#24,201
of 179,607 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#5
of 23 outputs
Altmetric has tracked 25,002,811 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,953 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,607 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.